RFK Jr. Set to Question Tylenol Use in Pregnancy with Autism Report

What Happened

U.S. Health Secretary Robert F. Kennedy Jr. is preparing to release a report examining whether there may be a connection between the use of Tylenol (acetaminophen) during pregnancy and an increased risk of autism in children. The report is also expected to address how folate-related deficiencies might affect neurological development and review potential treatment approaches involving compounds like folinic acid or leucovorin.

The document will not present conclusive findings but will argue that current research supports the need for further study. At present, the Food and Drug Administration, leading medical organizations, and the manufacturer of Tylenol continue to state that acetaminophen is considered safe for pregnant women when used appropriately.

While Kennedy has not yet issued public remarks about the report, he is expected to introduce it formally in the near future. If released as planned, it would mark one of the first major public health initiatives of his time in office, which began earlier this year under the Trump administration.

Why It Matters

If released as expected, the report could usher in a monumental change in the federal government’s approach to studying environmental and pharmaceutical factors in neurodevelopmental disorders. Acetaminophen is one of the most widely used medications in the world, especially among pregnant women, and is commonly recommended for fever and mild pain relief during pregnancy due to its safety profile.

The Freedom Dividend Might Cost You Big

They’re calling it ‘the Freedom Dividend.’

Free checks, no strings – paid out to people just doing what they already do on their phones: play games, use apps, and listen to music.

Tech titans like Elon Musk, Sam Altman, and Mark Zuckerberg are all pushing for Universal Basic Income because they know jobs are disappearing due to AI.

But here’s what everyone glosses over: Someone has to pay for it.

And if you’re accredited, wealthy, or asset-heavy… that “somebody” is probably you.

Unless…

You put yourself on the other side of the UBI equation.

Mode Mobile is already doing what governments can’t, and using attention as currency (instead of employment) to distribute income.*

Mode’s ecosystem turns screen time into cash flow, with 50M users that have earned over $325M to prove it.

They were crowned as 2023’s #1 fastest growing software company by Deloitte, after their revenue soared by an eye-popping 32,481%.

Their last two rounds were over subscribed at $0.30/share and space in the current round is limited.

And investors still have a window to get in before this becomes the template for post-AI income redistribution.

>>> Get all the details here

Although some observational studies have suggested a correlation between prenatal exposure to acetaminophen and increased risk of developmental conditions such as autism or ADHD, no conclusive causal link has been established. Most researchers agree that more controlled studies are needed.

Kennedy’s background as a critic of pharmaceutical oversight and vaccine policy has made his involvement in such topics controversial. Supporters argue that he is drawing attention to under-researched areas of public health. Critics worry that publicizing inconclusive evidence could undermine trust in safe and widely used medications.

The report’s inclusion of folate-related treatment options also touches on newer research into how nutritional support may help children with certain autism-related symptoms. Folinic acid, for example, has shown potential benefits in small clinical trials, though it remains far from a mainstream treatment.

How It Affects Readers

For expecting parents, this report could lead to new questions and conversations with doctors. While the FDA’s guidance remains unchanged, some patients may seek alternative options for managing pain or fever during pregnancy. Health care providers may also need to prepare for more questions about long-term developmental risks related to common over-the-counter medications.

For the medical community, the report could trigger renewed debate over how to communicate evolving science without causing unnecessary alarm. If the Department of Health and Human Services begins funding further studies, it could mean expanded research opportunities into how pharmaceuticals and prenatal environments influence child development.

At the policy level, the report could influence how health agencies set research priorities and evaluate whether new labeling or public guidance on acetaminophen is warranted. It may also spark more conversations about how the government communicates evolving science without undermining trust in established medications.

For families affected by autism, the focus on folate-based treatments may draw attention to emerging clinical approaches. While some early studies have shown promise, these therapies remain under investigation and are not yet part of standard care. Medical professionals stress that any treatment decisions should be made in consultation with qualified specialists.

*Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur.

The Deloitte rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period.

Please read the offering circular and related risks at invest.modemobile.com.

In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. Mode Mobile has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained here: https://www.sec.gov/Archives/edgar/data/1748441/000164117225025402/ex99.pdf